D-dimer as a potential prognostic marker

Pathology and Oncology Research

Volumn 18, Issue 3, 2012, Pages 669-674

  Nagy, Zsuzsanna ^a   Horváth, Orsolya ^a   Kádas, Julia ^a   Valtinyi, Dorottya ^a   László, Larisza ^a   Kopper, Bence ^b   Blaskó, György ^c  

^a Szent Imre Hospital   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Cancer; D dimer; LMWH; Prognostic marker; Solid tumors

Indexed keywords

D DIMER; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; COLON CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PANCREAS CANCER; RETROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BREAST NEOPLASMS; COLONIC NEOPLASMS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VENOUS THROMBOEMBOLISM;

EID: 84863985467     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9493-5     Document Type: Article

References (21)

1. Bouillard JB, Bouillaud S (1823) De l'Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general. Arch GenMed 1:188-204
2. Trousseau A (1865) Phlegmasia alba dolens. Clinique Medicale de l'Hotel Dieu de Paris 3:654-712
3. Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:492-496
4. Murchinson JT, Wylie L, Stockton DL (2004) Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer 91:92-95
5. Noble S, Pasi J (2010) Epidemiology and pathophysiology of cancer-associated thrombosis. Brit J Cancer 102:52-59
6. Kakkar AK (2005) Low molecular weight heparin and survival in patients with malignant disease. Cancer Control 12:22-30
7. Kakkar AK, Levine MN, Kadziola Z (2004) Low molecular weight heparin, therapy with deltaparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22:1944-1948
8. Klerk CPW, Smorenburg SM, Otten H-M et al (2005) The effect of low molecular weight heparin on survivcal in patients with advanced malignancy. J Clin Oncol 23:2130-2135
9. Tóvári J, Berecky B, Gilly R et al (2004) Effect of heparin treatment on the metastatization of melanoma in a preclinical model (in Hungarian). Magyar Onkológia 48:235-241
10. Lazo-Langer A, Gross GD, Spaans JN et al (2007) The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trial. Thromb Hemostasis 5:729-737
11. Niers TMH, Brüggeman LW, Van Sluis GL et al (2009) Long-term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis. Internat Soc Thrombosis Haemostasis 7:1595-1597
12. Mousa SA, Petersen LJ (2009) Anticancer properties of lowmolecular- weight heparin: preclinical evidence. Thromb Haemost 102:258-267
13. Borsig I (2010) Antimetastatic effect of heparins and modified heparins. Experimental evidence. Thrombosis Res 125(suppl 2): S66-S71
14. Kenessey I, Simon E, Futosi K et al (2009) Antimigratory and antimetastatic effect of heparin-derived 4-18 unit oligosaccharides in a preclinical humanmelanoma metastasis model. Thromb Haemost 102:1265-1273
15. Nadir Y, Brenner B (2010) Heparanase procoagulant effects and inhibition by heparins. Thromb Res 125(suppl 2):572-576
16. Kvolik S, Jukic M, Matijevic M et al (2010) An overview of coagulation disorders in cancer patients. Surg Oncol 29:e33-e46
17. Khorana AA, Kunderer NM, Culakova E et al (2008) Development and validation of a predictive model for chemotherapyassociated thrombosis. Blood 111:4902-4907
18. Doormaal FF et al (2011) Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 29:2701-2706
19. Zs N, Turcsik V, Gy B (2009) The effect of LMWH (Nadroparin) on Tumor progression. Pathol Oncol Res Path Oncol Res 15:689-692
20. Kulasingam V, Pavlou MR, Diamandis EP (2010) Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nature Cancer Rev 10:371-378
21. Moore RG et al (2009) A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112:40-46